BCAX
NASDAQ HealthcareBicara Therapeutics Inc. - Common Stock
Biotechnology
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
๐ Market Data
| Price | $21.67 |
|---|---|
| Volume | 294,390 |
| Market Cap | 1.42B |
| RSI (14-Day) | 46.1 |
| 200-Day MA | $16.22 |
| 50-Day MA | $20.09 |
| 52-Week High | $24.25 |
| 52-Week Low | $7.80 |
| Forward P/E | -7.13 |
| Price / Book | 2.94 |
๐ฏ Investment Strategy Scores
BCAX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (33/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Moon Shot (16/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find BCAX in your text
Paste any article, transcript, or post โ the tool will extract BCAX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.